---
title: "Phase 1 solid tumor biotech Aktis Oncology sets terms for $200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2026"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/271531423.md"
description: "Aktis Oncology, a Phase 1 biotech firm focused on targeted radiopharmaceuticals for solid tumors, has announced terms for a $200 million IPO, offering 11.8 million shares at $16 to $18 each. At the midpoint, the company would have a market cap of $860 million. The IPO is set to price the week of January 5, 2026, with J.P. Morgan and others as joint bookrunners. Aktis Oncology, founded in 2020, reported $6 million in revenue for the year ending September 30, 2025, and is developing treatments for various cancers."
datetime: "2026-01-05T14:48:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271531423.md)
  - [en](https://longbridge.com/en/news/271531423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271531423.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/271531423.md) | [繁體中文](https://longbridge.com/zh-HK/news/271531423.md)


# Phase 1 solid tumor biotech Aktis Oncology sets terms for $200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2026

Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, announced terms for its IPO on Monday.

The Boston, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Aktis Oncology would command a fully diluted market cap of $860 million.

Aktis Oncology is a clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. Its pipeline features Ac-AKY-1189 for Nectin-4-expressing cancers, now enrolling about 150 patients in a multi-site US Phase 1b trial with preliminary results expected in the first quarter of 2027, and Ac-AKY-2519 targeting B7-H3-expressing tumors with an IND filing planned for 2026. It also manages multiple domestic and international isotope supply partnerships, invests in an internal cGMP facility set to be operational in 2026, and holds a discovery collaboration for additional miniprotein radioconjugate programs.

Aktis Oncology was founded in 2020 and booked $6 million in revenue for the 12 months ended September 30, 2025. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are the joint bookrunners on the deal. It is expected to price the week of Monday, January 5, 2026.

## 相关资讯与研究

- [Algorae Pharmaceuticals Enters Second Drug Synergy Screening Program with Peter MacCallum Cancer Centre](https://longbridge.com/zh-CN/news/280935796.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-CN/news/280997570.md)
- [Eli Lilly: use of Foundayo with other GLP-1 receptor agonist medicines is not recommended](https://longbridge.com/zh-CN/news/281395748.md)
- [Astellas Speeds Pipeline, Eyes 10 Late-Stage Drugs by 2034](https://longbridge.com/zh-CN/news/281117306.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-CN/news/281411704.md)